Accentia Biopharmaceuticals, Inc.Tampa, FL United States
Company Description
Accentia Biopharmaceuticals is accentuating its positives and eliminating its negatives. The drug development company is focused on two development-stage drugs, multiple sclerosis drug Revimmune and BiovaxID, a possible vaccine for non-Hodgkin's lymphoma being developed by majority-owned subsidiary
| 324 S. Hyde Park Ave., Ste. 350 | Phone: 813-864-2554 | http://www.accentia.net |
| Tampa, FL 33606 | Fax: 813-258-6912 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Accentia Biopharmaceuticals, Inc. Rankings
Executives
| 16 executives listed for Accentia Biopharmaceuticals, Inc.'s Tampa, FL location. | ||
| Chairman and CEO | Francis O'Donnell | |
|---|---|---|
| President and General Counsel | Samuel Duffey | |
| Acting CFO and Controller | GarrisonHasara | |
Financials
| Company Type | PublicHeadquarters |
|---|---|
| Fiscal Year-End | September |
| 2011 Employees | 68 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Accentia Biopharmaceuticals, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
